ArticleAnatolian journal of cardiology2025
Identification of Biomarkers for Acute Myocardial Infarction Based on Cell Senescence Genes and Machine Learning.
Article in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aims to identify senescence-related biomarkers for ST-elevation myocardial infarction (STEMI) prognosis.
methodsRNA expression data for STEMI samples and controls were obtained from the gene expression omnibus (GEO) database, and cellular senescence genes were acquired from CellAge database. Differential and overlap analyses were used to identify differentially expressed cellular senescence-related genes (DE-SRGs) in STEMI samples. Differentially expressed cellular senescence-related genes were further analyzed by plotting receiver operating characteristic (ROC) curves and machine learning algorithms. Gene Set Enrichment Analysis (GSEA) was employed on each biomarker. Immune-related analyses, competing endogenous RNA (ceRNA) construction, and target drug prediction were performed on biomarkers.
resultsThis study identified 7 DE-SRGs for STEMI prognosis. Gene Set Enrichment Analysis results showed enriched pathways, including ribosomes, autophagy, allograft rejection, and autoimmune thyroid disease. Furthermore, T cells, CD4 memory resting T cells, gamma delta, monocytes, and neutrophils represented significantly different proportions between STEMI samples and controls. In addition, CEBPB was positively correlated with monocytes and neutrophils but negatively correlated with T-cell CD8. A ceRNA network was established, and 8 FDA-approved drugs were predicted.
conclusionThis study identified 7 cellular senescence-related biomarkers, which could lay a foundation for further study of the relationship between STEMI and cellular senescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.